Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.090 AlteredExpression disease BEFREE Further, lutein and oxidized lutein augmented the AMPK phosphorylation and activation of mitochondrion signaling molecule TFAM (protein expression) and mRNA expression of PGC-1α, TFAM, and nuclear respiratory factor 1 (responsible for mitochondria biogenesis) along with lowered reactive oxygen species in HG compared with control and metformin groups. 31529536 2019
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.090 AlteredExpression disease BEFREE Hyperglycemia impaired metformin-induced AMPK<sup>Thr172</sup> activation and enhanced phosphorylation of AMPK at serine-485 (AMPK<sup>Ser485</sup>). 31205529 2019
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.090 Biomarker disease BEFREE Reductions in AMPK activity potentiate the effects of acute OLZ treatment on blood glucose, whereas specifically targeting AMPK β1-containing complexes is sufficient to protect against OLZ-induced hyperglycemia.-Shamshoum, H., Medak, K. D., Townsend, L. K., Ashworth, K. E., Bush, N. D., Hahn, M. K., Kemp, B. E., Wright, D. C. AMPK β1 activation suppresses antipsychotic-induced hyperglycemia in mice. 31581839 2019
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.090 Biomarker disease BEFREE Nevertheless, intervention with repeated daily administration of short-acting activation of AMPK was found to mitigate hyperglycemia and hyperinsulinemia in four rodent models of metabolic disease and without the cardiac glycogen accretion noted with sustained pharmacologic AMPK activation. 30811418 2019
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.090 Biomarker disease BEFREE Hepatic FAM3A restoration activates ATP-P2 receptor-Akt and AMPK pathways to attenuate steatosis and hyperglycemia in obese diabetic mice. 29221790 2018
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.090 Biomarker disease BEFREE Here, we report that hyperglycemia inhibits AMPK pathway and subsequently reduces ADR induced DNA damage, resulting in decreased chemotherapeutic sensitivity of Adriamycin (ADR). 29941677 2018
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.090 Biomarker disease BEFREE Baicalin attenuates in vivo and in vitro hyperglycemia-exacerbated ischemia/reperfusion injury by regulating mitochondrial function in a manner dependent on AMPK. 28743390 2017
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.090 Biomarker disease BEFREE The AMPK inhibitor and anti-diabetic drug metformin may counteract everolimus-induced hyperglycemia, as well as enhancing anti-cancer efficacy. 28356082 2017
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.090 Biomarker disease BEFREE AMPK activation stimulates fatty acid oxidation, enhances insulin sensitivity, alleviates hyperglycemia and hyperlipidemia, and inhibits proinflammatory changes. 20222801 2010